Second Quarter 2026 Total Revenue of $63.3 million; Second Quarter 2026 Product Revenue of $57.4 million, +10% Y/Y Raising Lower End of 2026 Product Revenue Guidance:...
Barchart Research What to Expect from CERS Earnings CERS Generated July 29, 2026 Current Price $2.87 Consensus Rating Strong Buy Average Move 11.90% After Raising Guidance in April, What Has Cerus Left...
Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2026 financial results will be released on Thursday, July 30, 2026, after the close of the stock market. The Company will host a...
Cerus Corporation (Nasdaq: CERS) announced today a company-sponsored lunch symposium and a selection of abstracts at the International Society of Blood Transfusion (ISBT) 39 th International...
Refinancing extends maturity and lowers cost of capital Enhances financial flexibility and positions Cerus to drive sustainable growth ...
First Quarter 2026 Total Revenue of $59.9 million, Up 23% Over Prior Year; First Quarter 2026 Product Revenue of $53.7 million, Up 24% Over Prior Year Raising Full Year...
Barchart Research What to Expect from CERS Earnings CERS Generated April 29, 2026 Current Price $1.9200 EPS Estimate $$-0.03 Consensus Rating Moderate Buy Average Move 8.18% Cerus Spent a Year Building...
Cerus Corporation (Nasdaq: CERS) announced today the signing of a new, four-year supply agreement with Établissement Français du Sang (EFS), the French Blood Establishment, for the INTERCEPT Blood System....